Video Experimental Relacionado
Updated: Jun 18, 2026
08:43
Isolation of Endothelial Progenitor Cells from Healthy Volunteers and Their Migratory Potential Influenced by Serum Samples After Cardiac Surgery
Published on: February 14, 2017
Movilización de las células progenitoras endoteliales en pacientes con infarto agudo del miocardio
S Shintani1, T Murohara, H Ikeda
1Cardiovascular Research Institute and Department of Internal Medicine III, Kurume University, Japan.
Circulation
|June 13, 2001
Resumen
Las células progenitoras endoteliales (EPC) y sus precursores se movilizan en la sangre periférica durante los eventos isquémicos agudos en humanos. Este estudio demuestra un aumento de EPC y células mononucleares CD34 positivas después de un infarto de miocardio.
Área de la Ciencia:
- Investigación cardiovascular Investigación cardiovascular Investigación cardiovascular Investigación cardiovascular Investigación cardiovascular
- Biología de las células madre Biología de las células madre
- La Medicina Regenerativa es una Medicina Regenerativa.
Sus antecedentes:
- Las células progenitoras endoteliales (EPC) se encuentran en la sangre periférica y ayudan a la neovascularización.
- No se comprende bien la movilización de las EPC y sus precursores (células mononucleares CD34 positivas, MNC ((CD34+)) durante los eventos isquémicos humanos agudos.
Objetivo del estudio:
- Investigar la movilización de EPC y MNC ((CD34+) en pacientes que experimentan eventos isquémicos agudos.
- Para determinar la relación entre estas células y los niveles de factor de crecimiento endotelial vascular (VEGF).
Principales métodos:
- La citometría de flujo se utilizó para cuantificar los recuentos circulantes de MNC ((CD34+) en pacientes con infarto agudo de miocardio (AMI) y sujetos de control.
- Las células mononucleares de la sangre periférica (PB-MNCs) fueron cultivadas para evaluar la formación de EPC.
- Se midieron los niveles plasmáticos de VEGF y se correlacionaron con los recuentos de MNC ((CD34+).
Principales resultados:
- Los recuentos de MNC circulantes ((CD34+) aumentaron significativamente en pacientes con IAM, alcanzando su pico en el día 7 después del inicio, a diferencia de los controles.
- Los PB-MNC cultivados de pacientes con IAM produjeron más grupos de EPC y EPC en el día 7 en comparación con el día 1.
- Los niveles plasmáticos de VEGF alcanzaron su pico en el día 7 y se correlacionaron positivamente con los recuentos de MNC ((CD34+).
Conclusiones:
- Este estudio proporciona la primera evidencia clínica de la movilización de EPC y MNC ((CD34+) durante eventos isquémicos humanos agudos.
- Los EPC movilizados y sus precursores pueden desempeñar un papel en la respuesta a la isquemia aguda.
Más Videos Relacionados
Videos de Conceptos Relacionados
01:15Layers of the Heart Wall
The heart wall comprises three distinct layers: the epicardium, myocardium, and endocardium. The outermost layer, the epicardium, is the visceral layer of the serous pericardium, featuring a thin, transparent mesothelial surface and an inner layer of areolar connective tissue with fat deposits that increase with age.
The myocardium, the thickest layer, consists of cardiac muscle cells interconnected by intercalated discs and crisscrossing connective tissue fibers. These muscle fibers contract...
The myocardium, the thickest layer, consists of cardiac muscle cells interconnected by intercalated discs and crisscrossing connective tissue fibers. These muscle fibers contract...
01:21Myocarditis I: Introduction
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:22Pericarditis I: Introduction
Pericarditis is defined as the inflammation of the pericardium, the thin, sac-like membrane surrounding the heart. This condition can cause significant chest pain and other symptoms, often necessitating medical intervention. The pericardium has two layers: the inner visceral layer and the outer parietal layer, separated by a small amount of fluid that reduces friction during heartbeats.Types of PericarditisPericarditis can be classified into several types based on the duration and nature of the...
01:30Introduction Cardiac Emergencies
Cardiac emergencies are critical situations involving the heart that require immediate medical intervention to prevent severe complications or death. These emergencies often arise from underlying heart conditions that impair the heart's ability to function correctly.Types of Cardiac EmergenciesThe most common types of cardiac emergencies include Acute Coronary Syndrome (ACS), myocardial infarction (MI), cardiac arrest, and heart failure.Acute Coronary Syndrome (ACS)Acute Coronary Syndrome (ACS)...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...